Expertise in
6
conditions

Dr. Anup Banerjee

Pulmonary Medicine | Intensive Care Medicine
Gastonia Medical Specialty Clinic PA
1021 X Ray Dr, 
Gastonia, NC 
 (108.0 mi)
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
Gastonia Medical Specialty Clinic PA
1021 X Ray Dr, 
Gastonia, NC 
 (108.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Anup Banerjee is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Gastonia, North Carolina. Dr. Banerjee is highly rated in 6 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Excessive Daytime Sleepiness, Narcolepsy, Chronic Obstructive Pulmonary Disease (COPD), and Advanced Bronchoscopy. Dr. Banerjee is currently accepting new patients.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in NC
Hospital Affiliations
Caromont Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

GASTONIA MEDICAL SPECIALTY CLINIC PA
1021 X Ray Dr, Gastonia, NC 28054

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug, Biological
Study Drug: GSK3511294
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
Enrollment Status: Withdrawn
Publish Date: April 22, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials
Similar Doctors
Expertise in
15
conditions
Dr. Jay M. Hendler
Pulmonary Medicine | Intensive Care Medicine
Expertise in
15
conditions
Dr. Jay M. Hendler
Pulmonary Medicine | Intensive Care Medicine

Caromont Medical Group Inc

2525 Court Dr, 
Gastonia, NC 
 (0.2 mi)
704-834-2450
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jay Hendler is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Gastonia, North Carolina. Dr. Hendler is highly rated in 15 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Pneumonia, and Advanced Bronchoscopy. Dr. Hendler is currently accepting new patients.

Expertise in
20
conditions
Dr. Ramarao Suresh
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
20
conditions
Dr. Ramarao Suresh
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Carolinas Physicians Network Inc

10628 Park Rd, 
Charlotte, NC 
 (18.4 mi)
704-667-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ramarao Suresh is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Charlotte, North Carolina. Dr. Suresh is highly rated in 20 conditions, according to our data. His top areas of expertise are Lung Metastases, Bronchiolitis Obliterans, Industrial Bronchitis, Emphysema, and Gastrostomy. Dr. Suresh is currently accepting new patients.

Expertise in
23
conditions
Dr. Joseph A. Boscia
Pulmonary Medicine | Intensive Care Medicine
Expertise in
23
conditions
Dr. Joseph A. Boscia
Pulmonary Medicine | Intensive Care Medicine

Upstate Lung And Critical Care Specialists PC

151 Harold Fleming Ct, 
Spartanburg, SC 
 (49.5 mi)
864-573-6320
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients

Joseph Boscia is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Boscia is highly rated in 23 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Asbestosis, and Advanced Bronchoscopy. Dr. Boscia is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile